In this issue:
Real-life ixazomib-based frontline therapy in newly diagnosed MM
Daratumumab + RVd for transplant-eligible newly diagnosed MM
Mortality for MM inpatients with renal impairment undergoing autologous SCT
Different MAF translocations confer similar prognosis in newly diagnosed MM
Pomalidomide/cyclophosphamide/dexamethasone in relapsed/refractory MM
Lenalidomide maintenance after second autologous SCT improves OS
KRd vs. VRd in newly diagnosed MM intended for immediate autologous SCT
Double vs. triple bortezomib regimens in MM with acute kidney injury due to cast nephropathy
Maintenance vs. observation in transplant-ineligible, newly diagnosed MM
Thrombosis in Myeloma IX
Please login below to download this issue (PDF)